Pfizer and BioNTech Post Positive Trial Data for Their COVID-19 Vaccine
In an early-stage phase 1/2 clinical trial, BNT162b1, the COVID-19 vaccine being developed by Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX), produced antibodies against SARS-CoV-2, the novel coronavirus that causes COVID-19, after two doses.
Seven days after the second dose at the lowest two doses, 10 micrograms and 30 micrograms, 12 patients per group had antibodies capable of binding to the novel coronavirus that were 8 and 46.3 times higher, respectively, than the antibody levels of patients who had recovered from COVID-19.
More importantly, the antibodies were also able to keep the virus from infecting cells. The level of so-called neutralizing antibodies were 1.8- and 2.8-times higher than recovered patients at the 10-microgram and 30-microgram doses, respectively.
Source Fool.com
